Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trialReinhard Dummer, Keith T. Flaherty, Paolo A. Ascierto et al.|The Lancet Oncology|2018Cited by 1k
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Keith T. Flaherty, Michael D. Pickard et al.|The Lancet Oncology|2018Cited by 586
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trialJohn M. Kirkwood, Georgina V. Long, Michele Del Vecchio et al.|Nature Medicine|2023Cited by 208
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and managementHelen Gogas, Caroline Robert, Keith T. Flaherty et al.|European Journal of Cancer|2019Cited by 81
Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with CrossoverCélèste Lebbé, Brigitte Dréno, Caroline Dutriaux et al.|Cancers|2020Cited by 47